Literature DB >> 11262672

Prevalence of amblyopia and associated refractive errors in an adult population in Victoria, Australia.

S A Brown1, L M Weih, C L Fu, P Dimitrov, H R Taylor, C A McCarty.   

Abstract

The study aimed to describe the prevalence of amblyopia and associated refractive errors among an adult Australian population. The Visual Impairment Project (VIP) is a population-based study of age-related eye disease in the state of Victoria, Australia. Data were collected through standardised interviews and orthoptic and ophthalmic dilated examinations. Amblyopia was defined as best-corrected visual acuity of 6/9 or worse in the absence of any pathological cause. The participants were 3,265 urban residents and 1,456 rural residents of the VIP ranging in age from 40-92 years (mean = 59 years; 53% female). The prevalence of unilateral amblyopia was 3.06% (95% C.I. 2.59, 3.53). Amblyopia was not found to be statistically different by age group (p=0.096), gender (p=0.675), or place of birth (p=0.14). Anisometropia was statistically more common (p<0.001) in amblyopic cases (51.1%) compared to the normal population (9.7%), and 54% of amblyopic eyes had visual acuity of worse than 6/12. Amblyopia is a significant cause of unilateral reduced visual acuity in a population aged 40 years and older. Anisometropia was more prevalent and the degree of anisometropia was greater in the amblyopic group compared with the normal population. Oblique astigmatism was more prevalent in the amblyopic group compared with the normal population.

Entities:  

Mesh:

Year:  2000        PMID: 11262672

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  29 in total

1.  A randomised controlled trial of written information.

Authors:  P Lempert
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  A randomised controlled trial of written information.

Authors:  P Lempert
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 3.  Diagnostic accuracy of vision screening tests for the detection of amblyopia and its risk factors: a systematic review.

Authors:  Christine Schmucker; Robert Grosselfinger; Rob Riemsma; Gerd Antes; Stefan Lange; Wolf Lagrèze; Jos Kleijnen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

4.  The prevalence of amblyopia in Germany: data from the prospective, population-based Gutenberg Health Study.

Authors:  Heike M Elflein; Susanne Fresenius; Julia Lamparter; Susanne Pitz; Norbert Pfeiffer; Harald Binder; Philipp Wild; Alireza Mirshahi
Journal:  Dtsch Arztebl Int       Date:  2015-05-08       Impact factor: 5.594

5.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

Review 6.  Can perceptual learning be used to treat amblyopia beyond the critical period of visual development?

Authors:  Andrew T Astle; Ben S Webb; Paul V McGraw
Journal:  Ophthalmic Physiol Opt       Date:  2011-11       Impact factor: 3.117

Review 7.  Occlusion for stimulus deprivation amblyopia.

Authors:  Aileen Antonio-Santos; Satyanarayana S Vedula; Sarah R Hatt; Christine Powell
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

8.  Validation of dynamic random dot stereotests in pediatric vision screening.

Authors:  Anna Budai; András Czigler; Eszter Mikó-Baráth; Vanda A Nemes; Gábor Horváth; Ágota Pusztai; David P Piñero; Gábor Jandó
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-10-03       Impact factor: 3.117

9.  Visual outcomes and amblyogenic risk factors in craniosynostotic syndromes: a review of 141 cases.

Authors:  S H Khan; K K Nischal; F Dean; R D Hayward; J Walker
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

Review 10.  The relationship between anisometropia and amblyopia.

Authors:  Brendan T Barrett; Arthur Bradley; T Rowan Candy
Journal:  Prog Retin Eye Res       Date:  2013-06-15       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.